Comprehensive Alzheimer's Disease CRO Solutions for Drug Discovery

Tackle the complex challenges of Alzheimer's Disease with Cyagen's integrated research platform. We combine validated animal models, end-to-end CRO services, and expert-led strategy to accelerate the discovery of new AD therapeutics for scientists worldwide.

An Integrated Approach to AD Research & Its Challenges

Alzheimer's is the world's leading neurodegenerative disease, with a severe epidemiological outlook and vast unmet medical needs. While progress has been made in understanding key pathogenic mechanisms like Aβ plaques, tauopathy, and neuroinflammation, preclinical research still faces critical bottlenecks, including poor clinical translatability of models and a lack of standardized efficacy evaluation criteria.

To address these complex challenges, Cyagen provides a fully integrated workflow, from experimental design to final report delivery, ensuring your AD research project is efficient and seamlessly executed.

We have integrated advanced animal models, in vivo pharmacology, and in vitro analytical techniques to build a powerful research platform for Alzheimer's Disease, designed to meet your diverse R&D needs.

Our comprehensive portfolio of Alzheimer's Disease (AD) models is organized by key pathological targets to help you find the most relevant tools for your research. The table below includes both our validated, ready-to-use models for immediate deployment, and our advanced R&D platforms for foundational models like APP and APOE4, available for custom projects and collaborative research.

Target Class	Model Name	Key Features	Status	Details
Tauopathy	B6-htau	Humanized MAPT (Wild-Type)	Ready-to-Use	View
	B6-htau*P301L	Humanized MAPT (P301L Mutation)	Ready-to-Use	View
	B6-htau*P301S	Humanized MAPT (P301S Mutation)	Ready-to-Use	View
	B6-hTFRC/htau	Humanized TFRC & MAPT (WT)	Ready-to-Use	View
	B6-hTFRC/htau*P301L	Humanized TFRC & MAPT (P301L)	Ready-to-Use	View
	B6-hTFRC/htau*P301S	Humanized TFRC & MAPT (P301S)	Ready-to-Use	View
	B6-htau/hGLP-1R	Humanized MAPT & GLP-1R (WT)	Ready-to-Use	View
Aβ Pathology	hAPP	Humanized APP (Wild-Type)	R&D	-
Aβ Pathology	hAPP (NL-G-F-V)	Humanized APP (Swedish/Iberian/Arctic)	R&D	-
Key AD Risk Gene	B6-hAPOE4	Humanized APOE4 (Wild-Type)	R&D	-
Neuroinflammation	Trem2 KO	Trem2 Knockout	Ready-to-Use	View
Neuroinflammation	hTREM2	Humanized TREM2 (Wild-Type)	R&D	-

Can't find the model you need?

Explore hundreds of additional off-the-shelf neuroscience models in our MouseAtlas database, or partner with our scientific team to develop a custom-engineered model tailored to your exact research specifications.

Precision Drug Administration

Our team of skilled specialists is highly experienced in precision injection methodologies tailored for CNS research. We offer a comprehensive array of validated administration routes to ensure accurate and reliable delivery of your therapeutic candidates.

Systemic Delivery: Intravenous (tail vein), Intraperitoneal, Subcutaneous, etc.
CNS-Targeted Delivery: Stereotactic brain injection, Intrathecal injection, Intraventricular injection, and Intranasal administration.

Featured Technique: Stereotactic Brain Injection

Our stereotactic injection service enables targeted delivery to specific brain regions critical to AD pathology, such as the hippocampus and cortex, guided by 3D coordinates and verified through histological imaging.

Case Study: AAV Delivery to the CNS

Agent: AAV9-CMV-EGFP-HGH

Coordinates: -2mm, ±1.8mm, -1.5mm

Titer: 1.98×10¹⁴ vg/mL

Dose: 1×10¹⁰ vg/0.5μL/site

Imaging Time: 4 weeks post-injection

Figure: Precise injection site visualization using the brain stereotactic instrument.

Case Study: LPS-Induced Neuroinflammation Model

Agent: Lipopolysaccharide

Coordinates: +4.8mm, ±1.8mm, -8.0mm

Dose: 4μL/site (5 mg/mL)

Observation Time: 2 weeks post-injection

Observation: Rat displaying unidirectional rotational movement 14 days post-operation.

Figure: Significant behavioral changes observed 2 weeks post-injection.

Neurobehavioral Assessment for AD

We provide a focused suite of behavioral paradigms essential for evaluating the core cognitive and functional deficits associated with Alzheimer's Disease.

Behavioral Domain	Recommended Tests for AD Research	Function Tested
Learning & Memory	Morris Water Maze	Spatial learning and memory
	Y-Maze	Spatial working memory
	Novel Object Recognition	Recognition memory
	Fear Conditioning Test	Associative fear memory
Anxiety & Depression-like Behavior	Elevated Plus Maze	Anxiety-like behavior
Anxiety & Depression-like Behavior	Open Field Test	Locomotor activity and anxiety
Motor Function & Coordination	Rotarod Test	Motor coordination, balance, and ataxia
General Well-being	Nest Building	Assessment of well-being and cognitive decline

We offer a focused suite of analytical services to investigate the core pathological and molecular features of Parkinson's Disease, and to evaluate the efficacy of your therapeutic candidates.

Analysis Category	Specific Services	Key Applications & Targets in AD Research
Pathology & Biomarker Analysis	Histology & Special Stains (H&E, Congo Red)	Visualize general brain morphology and specifically identify dense-core amyloid plaques.
	Immunohistochemistry (IHC) / Immunofluorescence (IF)	Detect, localize, and quantify key pathological proteins directly in tissue sections (e.g., Aβ, p-Tau, Iba1 for microglia, GFAP for astrocytes).
	ELISA & Immunoassays	Accurately quantify levels of soluble/insoluble Aβ40/42, total Tau/p-Tau, and key inflammatory markers (e.g., cytokines) in brain tissue and plasma.
Gene & Protein Expression	Western Blot	Assess changes in protein levels and post-translational modifications (e.g., phosphorylation of Tau) for key biomarkers.
Gene & Protein Expression	RT-PCR & qPCR	Analyze the expression of target genes (e.g., APP, MAPT), inflammatory factors, and synaptic markers to understand mechanistic changes.
Physiological & Biochemical Analysis	Biochemical Panels	Assess the systemic impact of AD and therapeutic interventions by analyzing immune factors, antioxidant status, blood glucose, and lipid profiles.
Physiological & Biochemical Analysis	Metabolic Testing (ITT, GTT)	Evaluate metabolic dysregulation, a known comorbidity and potential driver of AD pathology.

Case Studies

Explore how we leverage our precision animal models and comprehensive service platforms to provide robust, decision-enabling data for our partners' AD drug discovery programs.

Case Study 1: Donepezil Ameliorates Aβ Pathology and Cognitive Deficits in 10-Month-Old APP/PS1 Mice

Case Study 2: A Comprehensive Validation Profile of the hMAPT Model Platform

Why Partner with Cyagen?

Comprehensive Model Solutions

Access a portfolio of ready-to-use, validated models and leverage our deep expertise in developing custom models on classic AD backgrounds.

Integrated Efficacy Platform

Utilize our one-stop, standardized services, from in-life behavioral studies to terminal molecular pathology.

Data-Driven Decision Support

Rely on our stringent quality control and commitment to reproducibility to deliver reliable data that supports your critical project decisions.

Expert-Led Study Design

Collaborate with our team of senior scientists to receive end-to-end support, from model selection to customized experimental protocol design.

Request a Preclinical CRO Services Consultation

Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.

Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:

Yes, I want to receive updates on products, services, and events from Cyagen.

You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.

By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.